title: Effect of anticholesterol therapy on soluble ICAM-1 in chronic stroke patients with hyperlipidemia.
abstract: OBJECTIVE
  We examined the effects of drug therapy with pravastatin (P) or bezafibrate (B) and diet (D) therapy on serum lipids and soluble intercellular adhesion molecule-1 (sICAM-1) in hyperlipidemic cerebrovascular disease (CVD) patients in the chronic stage.
  
  
  METHODS
  This study included 36 patients (28 with cerebral infarction and hyperlipidemia and eight with cerebral hemorrhage and hyperlipidemia) divided into three groups: Group P (12 patients), Group B (10 patients), and Group D (14 patients). Before and after treatment, total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), triglyceride (TG), high density lipoprotein cholesterol (HDL-C) and sICAM-1 levels were measured.
  
  
  RESULTS
  In Group P, Group B and Group D, TC levels were decreased by 30% (p < 0.005), 21% (p < 0.01), and 21% (p < 0.001), LDL-C levels were decreased by 38% (p < 0.005), 18% (not significant), and 25% (p < 0.005) and TG levels were decreased by 27% (p < 0.05), 53% (p < 0.005) and 22% (p < 0.05), respectively. sICAM-1 levels were decreased by 20% (p < 0.005) in Group P, but were not decreased in Group B or Group D. There was no correlation between deltaTC and delta sICAM-1 (r = 0.172).
  
  
  CONCLUSIONS
  Administration of pravastatin significantly reduced sICAM-1 levels, independently of its decreasing effect on TC and TG in chronic CVD patients. Pravastatin may exert anti-atherosclerotic activity via two distinct mechanisms.
authors.affiliation: Department of Internal Medicine, Tokai University School of Medicine, Boseidai, Isehara, Kanagawa 259-1193, Japan.
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Tomiyasu
authors.forename: Kiyoko
authors.initials: K
authors.lastname: Ishikawa
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yamamoto
authors.forename: Takashi
authors.initials: T
authors.lastname: Hata
authors.forename: Tami
authors.initials: T
authors.lastname: Ohta
authors.forename: Yasuhisa
authors.initials: Y
authors.lastname: Kitagawa
authors.forename: Yukito
authors.initials: Y
authors.lastname: Shinohara
mesh_terms: D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001629:Bezafibrate / Q000627:therapeutic use; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D002908:Chronic Disease / Q000188:drug therapy / Q000628:therapy; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood* / Q000150:complications / Q000628:therapy*; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood*; D008297:Male; D017035:Pravastatin / Q000627:therapeutic use; D012995:Solubility; D020521:Stroke / Q000097:blood* / Q000150:complications / Q000628:therapy*; D014280:Triglycerides / Q000097:blood
chemical_list: D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D014280:Triglycerides; D018799:Intercellular Adhesion Molecule-1; D017035:Pravastatin; D001629:Bezafibrate